Ariad Pharmaceuticals, Inc.  

(Public, NASDAQ:ARIA)   Watch this stock  
Find more results for ARIA
5.89
-0.29 (-4.74%)
Jul 25 - Close
NASDAQ real-time data - Disclaimer
Currency in USD
Range 5.82 - 6.16
52 week 2.15 - 23.00
Open 6.16
Vol / Avg. 10.84M/8.82M
Mkt cap 1.10B
P/E     -
Div/yield     -
EPS -1.40
Shares 186.80M
Beta 1.49
Inst. own 60%
Aug 6, 2014
Q2 2014 ARIAD Pharmaceuticals, Inc. Earnings Release - 9:30AM EDT - Add to calendar
Aug 6, 2014
Q2 2014 ARIAD Pharmaceuticals Inc Earnings Call - 8:30AM EDT - Add to calendar
Jun 25, 2014
ARIAD Pharmaceuticals, Inc. Annual Shareholder Meeting - Webcast
Jun 11, 2014
ARIAD Pharmaceuticals, Inc. at Goldman Sachs Healthcare Conference - Webcast
Jun 4, 2014
ARIAD Pharmaceuticals, Inc. at Jefferies Global Healthcare Conference - Webcast
Jun 2, 2014
ARIAD Investor and Analyst Briefing from ASCO - Webcast
May 20, 2014
ARIAD Pharmaceuticals, Inc. at UBS Global Healthcare Conference - Webcast
May 7, 2014
Q1 2014 ARIAD Pharmaceuticals, Inc. Earnings Release
May 7, 2014
Q1 2014 ARIAD Pharmaceuticals, Inc. Earnings Conference Call - Webcast
More events from DailyFinance »    

Key stats and ratios

Q1 (Mar '14) 2013
Net profit margin -422.87% -601.74%
Operating margin -421.41% -600.44%
EBITD margin - -591.36%
Return on average assets -55.78% -99.50%
Return on average equity -120.85% -183.77%
Employees 307 -
CDP Score - -

Address

26 LANDSDOWNE ST
CAMBRIDGE, MA 2139
United States - Map
+1-617-4940400 (Phone)
+1-617-4948144 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money

Description

ARIAD Pharmaceuticals, Inc. (ARIAD) is a global oncology company focused on the discovery, development and commercialization of medicines for the cancer patients. ARIAD�s first medicine, Iclusig, is approved in the United States for the treatment of adult patients with chronic, accelerated or blast phase chronic myeloid leukemia that is resistant or intolerant to prior tyrosine kinase inhibitor (TKI) therapy or Philadelphia chromosome-positive acute lymphoblastic leukemia that is resistant or intolerant to prior TKI therapy. As of January 11, 2013, additional clinical trials of Iclusig in other cancers were ongoing. As of January 11, 2013, ARIAD also studied AP26113, another molecularly targeted medicine, in certain forms of lung cancer.

Officers and directors

Harvey J. Berger M.D. Chairman of the Board, President, Chief Executive Officer
Age: 64
Bio & Compensation  - Reuters
Edward M. Fitzgerald Chief Financial Officer, Executive Vice President, Treasurer
Age: 59
Bio & Compensation  - Reuters
Martin J. Duvall Executive Vice President, Chief Commercial Officer
Age: 52
Bio & Compensation  - Reuters
David L. Berstein Esq. Senior Vice President, General Counsel and Chief Intellectual Property Counsel, and Secretary
Age: 62
Bio & Compensation  - Reuters
Maria E. Cantor Senior Vice President - Corporate Affairs and Human Resources
Age: 46
Bio & Compensation  - Reuters
Daniel M. Bollag Ph.D. Senior Vice President - Regulatory Affairs and Quality
Age: 53
Bio & Compensation  - Reuters
Hugh M. Cole Senior Vice President, Chief Business Officer
Age: 49
Bio & Compensation  - Reuters
Frank G. Haluska M.D., Ph.D. Senior Vice President - Clinical Research and Development and Chief Medical Officer
Age: 55
Bio & Compensation  - Reuters
Timothy P. Clackson Ph.D. President - Research and Development, Chief Scientific Officer
Age: 49
Bio & Compensation  - Reuters
Wayne R. Wilson Lead Independent Director
Age: 65
Bio & Compensation  - Reuters